Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement August 4, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference August 4, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference July 30, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference July 27, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders July 21, 2020 • 4:45 PM EDT
Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics July 16, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering July 15, 2020 • 5:00 PM EDT
Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering July 13, 2020 • 1:11 PM EDT
Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19 July 13, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia July 10, 2020 • 7:00 AM EDT
